Wild Arabic Herbs – FDA Warning Letter, May 1, 2026

The U.S. Food and Drug Administration (FDA) issued a warning letter to Wild Arabic Herbs on June 17, 2026, following a review of the company’s website conducted in May 2026. The FDA determined that the firm is marketing a product named "Edral-17t" as an unapproved new drug, which violates the Federal Food, Drug, and Cosmetic Act. According to the letter, the company"s website promoted "Edral-17t" as a treatment for serious medical conditions, including prostate and testicular cancers. The marketing materials claimed the product possessed anticancer and anti-metastatic effects, such as inhibiting tumor cell growth and preventing the spread of malignant cells. Under federal law, products intended to treat or prevent disease must be proven safe and effective through an FDA approval process before they can be sold. Because "Edral-17t" lacks such approval, its distribution is considered a violation of federal safety standards. The FDA has instructed Wild Arabic Herbs to immediately address these violations and investigate the underlying causes of the non-compliance. The company must provide a written response within 15 business days detailing the specific steps taken to correct the issues and prevent their recurrence. Failure to comply with these requirements may lead to regulatory actions, such as the seizure of products or legal injunctions.